November 20, 2026

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer, President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Executive Officer, CSO
Takuya Kaneko
(TEL. 03-6214-3600)

GNI Group Celebrates 25th Anniversary: From Drug Discovery to Commercialization, Connecting the World for the Next Stage of Growth

— Leveraging Our Global Network, Deep Local Market Expertise, and Agility to Bring Innovative Treatment Options to Patients Worldwide —

GNI Group Ltd. (Tokyo Stock Exchange: 2160, the "Company") celebrates its 25th anniversary on November 20, 2026. Since its establishment in 2001, the Company has evolved from genetic analysis to drug discovery, expanding its business through the commercialization of pharmaceuticals in China, research and development and medtech operations in the United States, and the strengthening of its business foundation in Japan. In 2026, the Company acquired all shares of AYUMI Pharmaceutical Holdings Co., Ltd. ("AYUMI Pharmaceutical"), further expanding its pharmaceutical business in Japan. Leveraging its business operations across Japan, China, the United States, and Australia, the Group is now entering its next stage of growth.



Group executives from Japan and overseas gathered in Japan for the Group's Strategic Management Meeting (October 2026).

25 Years of Evolution: Building a Strong Business Foundation Through Change

The Company was established on November 20, 2001, in Shibuya, Tokyo, as Gene Networks, Inc. Initially focused on drug discovery using genetic analysis technologies, the Company shifted its strategic focus toward full-scale drug discovery in 2008.
In 2014, the Group launched ETUARY™ in China for the treatment of idiopathic pulmonary fibrosis (IPF), marking a significant milestone in translating research and development into commercial products. The Group subsequently expanded its drug discovery and medtech operations in the United States. In 2026, the addition of AYUMI Pharmaceutical, whose product portfolio includes CALONAL®, further strengthened the Group's presence in Japan's pharmaceutical market.

Three Business Segments: Pharmaceuticals, Drug Discovery, and Medtech

Pharma
In Japan, AYUMI Pharmaceutical markets pharmaceutical products in the areas of pain management, rheumatoid arthritis, and osteoporosis.
In China, the Group markets ETUARY® (pirfenidone), a treatment for IPF. F351, a drug candidate for the treatment of liver fibrosis associated with chronic hepatitis B, is currently undergoing regulatory review following the submission of a New Drug Application (NDA) in China. The Group believes that a decision on the application may be issued by the end of 2026 or in the first quarter of 2027.

Biotech
The Group is advancing the development of next-generation therapeutics in oncology, inflammatory diseases, pain management, and other therapeutic areas, leveraging its proprietary targeted protein degradation (TPD) technology.

Medtech
In the United States, the Group manufactures and sells biomaterials. In Japan, ZOO LABO, Inc., one of the country's major dental laboratories, joined the Group in December 2025.

2026: Strengthening Our Business Foundation in Japan

The addition of AYUMI Pharmaceutical marked an important milestone, bringing an established sales infrastructure and extensive pharmaceutical business expertise in Japan to the Group.
This has strengthened the Group's ability to explore and pursue the introduction and commercialization of pharmaceuticals and biosimilars from overseas markets in Japan, alongside its own development pipeline. The Group aims to accelerate efforts to connect its research and development achievements with the medical needs of patients in each market.

GNI Group's Distinctive Strengths: Global Collaboration × Deep Local Market Expertise × Agility

Having operations in multiple countries is not, in itself, the Group's competitive advantage. Rather, its strength lies in the ability to connect the business foundations and trusted relationships established in individual markets through

a cross-border network spanning research and development, manufacturing, and sales, while enabling swift decision-making.
As geopolitical tensions, differences in regulatory and healthcare systems, and changing market conditions create an increasingly complex global environment, the ability to collaborate flexibly across regions while maintaining a deep understanding of local circumstances is becoming more important than ever.
Building on these strengths, the Group will deepen collaboration among its operations in Japan, China, the United States, and Australia, with the aim of delivering innovative medicines and treatment options to patients in need, in compliance with applicable regulations in each country and region.

Message from Dr. Ying Luo, Representative Executive Officer, President and CEO

"On the occasion of our 25th anniversary, I would like to express my sincere gratitude to our patients, healthcare professionals, shareholders and investors, and employees for their continued support.
Over the past 25 years, we have embraced change and continued our journey to translate the potential of science into new treatment options for patients. Our transformation into a drug discovery company, the commercialization of pharmaceuticals, and the establishment of business foundations across different regions have each played an essential role in shaping the GNI Group we are today.
The addition of AYUMI Pharmaceutical to our Group in 2026 marks the beginning of our next stage of growth. By leveraging our global perspective and network, deep local knowledge and trusted relationships, and the agility to adapt to change, we will continue to take on new challenges, overcoming geographical and market barriers to bring innovative medicines and treatment options to patients around the world."

Corporate Milestones

Year	Key Milestones
2001	Established as Gene Networks, Inc. in Shibuya, Tokyo, Japan.
2002	Commenced joint research with Shanghai Genomics.
2005	Acquired Shanghai Genomics as a subsidiary (subsequently entered into an agreement in 2007 to make it a wholly owned subsidiary).
2007	Listed on the Tokyo Stock Exchange Mothers Market (now the Growth Market) in August.
2008	Dr. Ying Luo assumed the position of Representative Director, President and CEO. The Company shifted its strategic focus from genetic analysis to full-scale drug discovery.
2014	Launched ETUARY™ in China.
2017	Acquired Berkeley Advanced Biomaterials (BAB) in the United States as a subsidiary.
2018	Established Cullgen in the United States (currently a consolidated subsidiary of the Company).
2021	F351 received Breakthrough Therapy Designation from the Chinese regulatory authorities.
2023	Gyre Therapeutics, a consolidated subsidiary of the Company, was listed on the Nasdaq Stock Market (NASDAQ: GYRE).
2025	• Announced that the Phase 3 clinical trial of F351 in China had met its primary endpoint. • Acquired ZOO LABO as a subsidiary.
2026	• March: Submitted the NDA for F351 in China (formally accepted in May). • July: Completed the acquisition of all shares of AYUMI Pharmaceutical Holdings.

	• October: Included in the TOPIX (Tokyo Stock Price Index). • November 20: Celebrated the Company's 25th anniversary.

About GNI Group

GNI Group is a global biopharmaceutical company headquartered in Japan, with operations in Japan, China, the United States, and Australia. The Group operates an integrated business spanning drug discovery, pharmaceutical development and commercialization, and medtech.

The Group has established in-house capabilities covering the entire process from innovative drug discovery and basic research using its proprietary targeted protein degradation (TPD) platform technology to global clinical development. Its development pipeline includes F351, its lead drug candidate for the treatment of liver fibrosis associated with chronic hepatitis B, a condition for which no effective treatment is currently available, as well as candidates targeting a broad range of therapeutic areas, including fibrosis, oncology, inflammatory diseases, and pain management.

In addition, the Group has built a strong foundation for its next stage of growth through stable manufacturing capabilities spanning raw material production to finished product manufacturing, an extensive sales network supported by its own medical representatives (MRs) covering healthcare institutions, and contract manufacturing services.

GNI Group Website: https://www.gnipharma.com/english/